Browse 226 esophageal cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
There are two main types of esophageal cancer, and in the United States the more common one is now adenocarcinoma, linked to long term acid reflux and a condition called Barrett's esophagus. Because the esophagus stretches easily, symptoms such as trouble swallowing often appear only after the cancer has grown. Outcomes improve most when cancer is found early and treated with combinations, and trials are testing immunotherapy, targeted drugs, and better ways to spot cancer in people with Barrett's esophagus before it develops.
Location: Boston MA, New York NY, Philadelphia PA, Syracuse NY,
Sponsor: Genmab
Sex: All
Age: 18+
Code: NCT03526835
Phase 1, Phase 2, Recruiting
Registry for Esophageal and Gastroesophageal Junction Cancer
for
Gastroesophageal-junction Cancer, Esophageal Cancer
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 18+
Code: NCT06558786
Recruiting
Quality of Life Assessment of Cryotherapy in Esophageal or Gastroesophageal Cancer
for
Esophageal Cancer
Location: Goodyear AZ
Sponsor: Western Regional Medical Center
Sex: All
Age: 18 - 70+
Code: NCT03285035
Recruiting
Brodalumab in the Treatment of Immune-Related Adverse Events
for
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer,
Location: New York NY
Sponsor: Brian Henick, MD
Sex: All
Age: 18+
Code: NCT06673329
Phase 1, Recruiting
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
for
Gastric Adenocarcinoma, Oligometastasis,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18 - 70+
Code: NCT03161522
Phase 2, Recruiting
Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy
for
Esophageal Cancer Surgery, Esophagectomy,
Location: Cleveland OH
Sponsor: The Cleveland Clinic
Sex: All
Age: 18+
Code: NCT06721520
Phase 2, Phase 3, Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Location: East Syracuse NY, Pittsburgh PA, Grand Rapids MI,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06469944
Phase 1, Phase 2, Recruiting
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors